| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
PD-L1-IN-9 (compound Z38) (48 hours) showed low cytotoxicity against B16-F10, Jurkat, HepG2, HCT116 and HeLa cell lines, with IC50 values ranging from 28.18 μM to >40 μM[1]. PD-L1-IN-9 (1.5625–25 μM; 48 hours) induced HepG2 cell death in a dose-dependent manner by reactivating T cells in a HepG2/Jurkat co-culture system[1].
|
|---|---|
| ln Vivo |
PD-L1-IN-9 (compound Z38) (15-30 mg/kg; intraperitoneal injection; 7 days) inhibited tumor growth in B16-F10 melanoma mice in a dose-dependent manner [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: HepG2/Jurkat T cell co-culture system Tested Concentrations: 1.5625, 3.125, 6.25, 12.5 and 25 μM Incubation Duration: 48 hours Experimental Results: Promoted dose-dependent death of HepG2 cells. At 25 μM, the survival rate of HepG2 cells was reduced to 75.26% by reactivating Jurkat T cell-mediated killing. |
| Animal Protocol |
Animal/Disease Models:C57BL/6 (male, 6 weeks old, melanoma model established by subcutaneous injection of B16-F10 cells)[1]
Doses: 15, 30 mg/kg Route of Administration: Intraperitoneal injection; daily; for 7 consecutive days Experimental Results: At a dose of 15 mg/kg, the tumor growth inhibition rate (TGI) reached 34%, the number of tumor-infiltrating CD4⁺ T cells increased to 14.9%, the number of CD8⁺ T cells increased to 22.4%, and the PD-L1 degradation rate in the tumor tissue was approximately 49%. At a dose of 30 mg/kg, the number of CD4⁺ T cells in the tumor tissue increased to 19.3%, the number of CD8⁺ T cells increased to 26.6%, and the PD-L1 degradation rate in the tumor tissue reached 60%. |
| References |
| Molecular Formula |
C29H29N3O4
|
|---|---|
| Molecular Weight |
483.56
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1=C(C2=NC(N(C)C=C3CN4CC[C@@H](C(O)=O)C4)=C3C=C2)C=CC=C1C5=CC6=C(OCCO6)C=C5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0680 mL | 10.3400 mL | 20.6800 mL | |
| 5 mM | 0.4136 mL | 2.0680 mL | 4.1360 mL | |
| 10 mM | 0.2068 mL | 1.0340 mL | 2.0680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
